These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1720702)

  • 1. Biochemical studies on red blood cells from a patient with the Inab phenotype (decay-accelerating factor deficiency).
    Reid ME; Mallinson G; Sim RB; Poole J; Pausch V; Merry AH; Liew YW; Tanner MJ
    Blood; 1991 Dec; 78(12):3291-7. PubMed ID: 1720702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular basis of reduced or absent expression of decay-accelerating factor in Cromer blood group phenotypes.
    Lublin DM; Mallinson G; Poole J; Reid ME; Thompson ES; Ferdman BR; Telen MJ; Anstee DJ; Tanner MJ
    Blood; 1994 Aug; 84(4):1276-82. PubMed ID: 7519480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decay-accelerating factor (CD55) deficiency phenotypes in Japanese.
    Daniels GL; Green CA; Mallinson G; Okubo Y; Hori Y; Kataoka A; Kaihara M
    Transfus Med; 1998 Jun; 8(2):141-7. PubMed ID: 9675792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the defect which causes absence of decay accelerating factor (DAF) from the peripheral blood cells of an individual with the Inab phenotype.
    Tate CG; Uchikawa M; Tanner MJ; Judson PA; Parsons SF; Mallinson G; Anstee DJ
    Biochem J; 1989 Jul; 261(2):489-93. PubMed ID: 2476116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the sensitivity to complement-mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor).
    Merry AH; Rawlinson VI; Uchikawa M; Daha MR; Sim RB
    Br J Haematol; 1989 Oct; 73(2):248-53. PubMed ID: 2479410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular cloning and characterization of decay-accelerating factor deficiency in Cromer blood group Inab phenotype.
    Wang L; Uchikawa M; Tsuneyama H; Tokunaga K; Tadokoro K; Juji T
    Blood; 1998 Jan; 91(2):680-4. PubMed ID: 9427725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
    Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
    J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF.
    Telen MJ; Hall SE; Green AM; Moulds JJ; Rosse WF
    J Exp Med; 1988 Jun; 167(6):1993-8. PubMed ID: 2455016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired and transient RBC CD55 deficiency (Inab phenotype) and anti-IFC.
    Matthes T; Tullen E; Poole J; Banks J; Nagy M; Stelling MJ; Boehlen F; Michel M; Beris P; Hustinx H; Crew V; Daniels G
    Transfusion; 2002 Nov; 42(11):1448-57. PubMed ID: 12421218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycosyl phosphatidylinositol-linked blood group antigens and paroxysmal nocturnal hemoglobinuria.
    Telen MJ
    Transfus Clin Biol; 1995; 2(4):277-90. PubMed ID: 8542026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cromer-related antigens--blood group determinants on decay-accelerating factor.
    Daniels G
    Vox Sang; 1989; 56(4):205-11. PubMed ID: 2474898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement sensitivity of erythrocytes in a patient with inherited complete deficiency of CD59 or with the Inab phenotype.
    Shichishima T; Saitoh Y; Terasawa T; Noji H; Kai T; Maruyama Y
    Br J Haematol; 1999 Feb; 104(2):303-6. PubMed ID: 10050712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel molecular basis of an Inab phenotype.
    Hue-Roye K; Powell VI; Patel G; Lane D; Maguire M; Chung A; Reid ME
    Immunohematology; 2005; 21(2):53-5. PubMed ID: 15954804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Inab phenotype: characterization of the membrane protein and complement regulatory defect.
    Telen MJ; Green AM
    Blood; 1989 Jul; 74(1):437-41. PubMed ID: 2473800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dr(a-) polymorphism of decay accelerating factor. Biochemical, functional, and molecular characterization and production of allele-specific transfectants.
    Lublin DM; Thompson ES; Green AM; Levene C; Telen MJ
    J Clin Invest; 1991 Jun; 87(6):1945-52. PubMed ID: 1710232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum.
    Wilcox LA; Ezzell JL; Bernshaw NJ; Parker CJ
    Blood; 1991 Aug; 78(3):820-9. PubMed ID: 1713516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report and literature review: transient Inab phenotype and an agglutinating anti-IFC in a patient with a gastrointestinal problem.
    Yazer MH; Judd WJ; Davenport RD; Dake LR; Lomas-Francis C; Hue-Roye K; Powell V; Reid M
    Transfusion; 2006 Sep; 46(9):1537-42. PubMed ID: 16965581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cromer blood group system: a review.
    Storry JR; Reid ME; Yazer MH
    Immunohematology; 2010; 26(3):109-18. PubMed ID: 21214297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of the paroxysmal nocturnal hemoglobinuria phenotype in normal human erythrocytes: effects of 2-aminoethylisothiouronium bromide on membrane proteins that regulate complement.
    Ezzell JL; Wilcox LA; Bernshaw NJ; Parker CJ
    Blood; 1991 Jun; 77(12):2764-73. PubMed ID: 1710519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of Cromer blood group antigens.
    Lublin DM; Kompelli S; Storry JR; Reid ME
    Transfusion; 2000 Feb; 40(2):208-13. PubMed ID: 10686005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.